Researchers are exploring various approaches to predict and manage the progression of relapsing-remitting multiple sclerosis, including the use of biomarkers and artificial intelligence. Some studies suggest that certain biomarkers, such as serum neurofilament light chain, may be useful in predicting disease activity and worsening. The field is actively investigating new therapeutic strategies and diagnostic tools, with some treatments showing promise in pausing disease activity for extended periods.